Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan

Kang, Jeonggyu; Lai, Yen-Ling; Cheng, Wen‐Fang; Kim, Hyunsoo; Kuo, Kuan‐Ting; Chen, Yuli; Lee, Yoo-Young

doi:10.1038/s41598-020-77075-1

Cited by 13 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 The same result was also found in another study of which the advanced stage (III-IV) had a shorter median DFS than that of the early stage (I-II). 14 Our data indicated that patients with grade III had 3.4 times that of recurrence and five times the risk of death compared to those in grade I patients. This conforms with the results of a study of 506 patients, the grade of cancer was a significant factor that affected DFS, even though it was not significant for OS.…”

Section: Discussionmentioning

confidence: 53%

Correlation between clinicopathological factors and clinical outcomes of recurrent epithelial ovarian cancer at a tertiary hospital in Surabaya, Indonesia

2022

View full text Add to dashboard Cite

Introduction: Ovarian cancer is one of the leading causes of cancer death in women globally. The objective of this study was to determine the correlation and the association between age, stage, histopathology, grade, ascites, tumor residual, CA-125 level, and type of surgery on recurrence, disease-free survival, overall survival and mortality of epithelial ovarian cancer patients. Methods: An analytical retrospective study using medical records and interviews of epithelial ovarian cancer patients was conducted in Dr. Soetomo Hospital. The study included the data from January 2016-December 2020. Kaplan-Meier and log-rank test were used to assess the factors associated with disease-free survival (DFS) and overall survival (OS). Results: A total of 358 patients with epithelial ovarian cancer from 2016 to 2020 were included in the study of which 153 of recurrence cases. Clinicopathological factors that correlated with disease-free survival were stage, histopathology, grade, ascites, tumor residual, CA-125, and type of surgery (p<0.05). The factors that correlated with overall survival were stage, histopathology, grade, ascites, residual tumor, and CA-125 value (p<0.05). The most significant factors associated with recurrence and mortality were stage, grade, and ascites. Stage II and III had an HR (hazard ratio) of 1.9 and 2.1 for recurrence compared to stage I, respectively. Grade II and III patients had HRs of 2.1, and 3.4 for recurrence compared to stage I, respectively. The presence of ascites had an HR of 1.5 compared to those had no ascites. Stage III had an HR of 1.9 for mortality compared to stage I, respectively. Grade II and III patients had HRs of 3.6, and 5.0 for death compared to stage I, respectively. The presence of ascites had an HR of 1.6 compared to patients with no ascites. Compared to serous type, those patients with mucinous and clear cell had HR of 1.8 and 3.1 for mortality, respectively Conclusion: Stage, grade, and ascites were the most significant factors in the incidence of recurrence and mortality of epithelial ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 53%

Correlation between clinicopathological factors and clinical outcomes of recurrent epithelial ovarian cancer at a tertiary hospital in Surabaya, Indonesia

2022

View full text Add to dashboard Cite

show abstract

“…We analyzed the data from 6063 EOC cancer patients in 17 studies ( 6 , 14 , 15 , 17 – 19 , 23 , 24 , 26 , 27 , 30 – 36 ) to determine the relationship between pretreatment serum CA-125 level and OS. A random-effects model was employed based on the results of the heterogeneity analysis (I 2 = 86.40%, p <0.001).…”

Section: Resultsmentioning

confidence: 99%

“…Data from 13 studies with a total of 7145 patients were retrieved and utilized in the PFS analysis ( 16 – 18 , 21 , 22 , 25 , 26 , 30 – 32 , 36 – 38 ). The integrated data showed that increased serum CA-125 level before treatment was associated with poor PFS (HR=1.59, 95%CI=1.44-1.76, p<0.001, Figure 4 ).…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis

Wang

Liu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundCA-125 is a clinical biomarker with predictive effect on the prognosis of different cancers. Numerous clinical trials have been conducted to investigate the possibility of using the pretreatment level of CA-125 to predict the prognosis of epithelial ovarian cancer (EOC). However, its value in predicting prognosis remains controversial. The purpose of this meta-analysis was to assess the predictive value of pretreatment CA-125 levels for prognosis in EOC patients.MethodsWe searched the EMBASE, Cochrane library, PubMed and Web of Science databases for studies published up to 3 December 2021, according to specific inclusion and exclusion criteria. The clinical studies that were included investigated the relationship between pretreatment CA-125 levels and ovarian cancer prognosis. Combined hazard ratios (HR) of overall survival (OS) and progression-free survival (PFS) reported in the studies were compared and analyzed using fixed-effects/random-effects models. Sensitivity analysis was used to assess study stability, while Egger’s and Begg’s tests were used to assess publication bias.ResultsThis meta-analysis included 23 studies published in 2004 - 2021 with a total of 10,594 EOC patients. Comprehensive analysis demonstrated that the serum level of CA-125 before treatment was significantly correlated with overall survival (OS: HR=1.62, 95%CI=1.270-2.060, p<0.001) and progression-free survival (PFS: HR=1.59, PFS: HR=1.59, 95%CI=1.44~1.76, p<0.001). After comparing data from different FIGO stages and treatments, we discovered that a high pre-treatment serum CA-125 level was associated with a low survival rate.ConclusionAccording to the results of this study, a higher pre-treatment serum CA-125 level is associated with poor survival outcomes, which can be utilized to predict the prognosis of EOC patients. Pre-treatment serum CA-125 level might provide reliable basis for predicting the risk of EOC disease progression. This study is registered with the International Prospective Register of Systematic Reviews (CRD42022300545).Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=300545, identifier [CRD42022300545].

show abstract

“…Surgery is the fundamental treatment of LGSOC. FIGO stage and postoperative residual lesion are recognized as the prognostic factors of low-grade serous ovarian cancer [22]. In addition, age of diagnosis, body mass index (BMI) [23] and smoking [24] are also considered to be prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

The expression and clinical significance of C1orf106 in low-grade serous ovarian cancer

Song

Chen

Zhou

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Low-grade serous ovarian cancer is a rare subtype of ovarian cancer and lack of large-scale systematic studies worldwide.This study is aimed to select the target gene and figure out the expression and clinical significance of it in low-grade serous ovarian cancer. Methods and Results The mRNA data was downloaded from the Gene Expression Omnibus (GEO), then the differentially expressed genes (DEGs) between cancer and normal tissue were screened out by R software. Under comprehensive consideration, C1orf106 was chosen as our target gene based on the significant |logFC|, known molecular function and research innovation. Immunohistochemistry and qRT-PCR both showed that C1orf106 was highly expressed in tumor tissue. Contacted with clinical information, high-expression of C1orf106 was associated with lower Body Mass Index (< 25kg/m2) and no residual lesion. Kaplan-Meier analysis showed that high-expression of C1orf106 was associated with better overall survival, but may not be correlated with progression-free survival. COX regression model indicated that C1orf106 was one of the prognostic factor for low-grade serous ovarian cancer, but not independently. Conclusion C1orf106 was highly expressed in low-grade serous ovarian cancer. High expression of C1orf106 indicated a better overall survival. Therefore, C1orf106 may be one of the biomarkers with diagnostic and prognostic value in low-grade serous ovarian cancer, but the precise mechanism still needs further research.

show abstract

Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan

Cited by 13 publications

References 42 publications

Correlation between clinicopathological factors and clinical outcomes of recurrent epithelial ovarian cancer at a tertiary hospital in Surabaya, Indonesia

Correlation between clinicopathological factors and clinical outcomes of recurrent epithelial ovarian cancer at a tertiary hospital in Surabaya, Indonesia

Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis

The expression and clinical significance of C1orf106 in low-grade serous ovarian cancer

Contact Info

Product

Resources

About